{"id":3074,"date":"2025-03-04T15:58:05","date_gmt":"2025-03-04T12:58:05","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3074"},"modified":"2025-03-07T12:54:37","modified_gmt":"2025-03-07T09:54:37","slug":"capricor-therapeutics-announces-fda-acceptance-for-deramiocel-to-treat-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/capricor-therapeutics-announces-fda-acceptance-for-deramiocel-to-treat-duchenne-muscular-dystrophy\/","title":{"rendered":"Capricor Therapeutics annonce l&#039;acceptation et l&#039;examen prioritaire de sa demande de licence de produit biologique pour Deramiocel pour le traitement de la dystrophie musculaire de Duchenne"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Capricor Therapeutics, a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the U.S. Food and Drug Administration (\u201cFDA\u201d) has accepted for review its Biologics License Application (\u201cBLA\u201d) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (\u201cDMD\u201d) cardiomyopathy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Additionally, the FDA granted the BLA Priority Review with a Prescription Drug User Fee Act (\u201cPDUFA\u201d) target action date of August 31, 2025 and at this time, the FDA has not identified any potential review issues. [<a href=\"https:\/\/dmdwarrior.com\/capricor-therapeutics-submits-application-for-treatment-of-dmd-cardiomyopathy\/\" target=\"_blank\" rel=\"noreferrer noopener\">About Deramiocel<\/a>]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Capricor Therapeutics, a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the U.S. Food and Drug Administration (\u201cFDA\u201d) has accepted for review its Biologics License Application (\u201cBLA\u201d) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (\u201cDMD\u201d) [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3075,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[90,86,87,89,85,88],"class_list":["post-3074","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-cap-1002","tag-capricor","tag-capricor-therapeutics","tag-cardiomyopathy","tag-deramiocel","tag-fda"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=3074"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3074\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/3075"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=3074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=3074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=3074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}